I not sure about the assumptions. The main reason for USA is that at the time of planning, Australia did not have a break out.
- Better control of how test is conducted
Given the trial is done with people at home, im not sure if this would vary anywhere in the world
- Can instantly modify Algorithm if needed
I dont see how geography has anything to do with timing of data transfer. The subjects need internet no matter where they are an internet is internet
- Have more control of the hospitals used and the patients tested
I recall tests are being sent to people upon requests. I dont think hospitals are involved
- Would be cheaper to run- Results faster and Prof here to oversee
I think main costs are postage and the tests. I cant imagine they differ vastly across th world. India would presumably be cheaper.
- Importantly know what to expect before trialling In other countries
- a bad result will be hard to come back from.
Im pretty comfortable with their approach
- Forums
- ASX - By Stock
- RAP
- Ann: ResAppDx receives regulatory approval in Indonesia
Ann: ResAppDx receives regulatory approval in Indonesia, page-25
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online